Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor

PHASE3RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 11, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

April 1, 2026

Conditions
Intradialytic Hypotension
Interventions
DRUG

Icatibant

Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).

DRUG

Placebo

0.9% sodium chloride will be administered as the same rate as icatibant

Trial Locations (1)

37212

RECRUITING

Vanderbilt Fresenius, Nashville

All Listed Sponsors
collaborator

Pharvaris Netherlands B.V.

INDUSTRY

collaborator

Renal Research Institute

OTHER

lead

Vanderbilt University Medical Center

OTHER